SEC Tracker
Get the app

Nu-Med Plus NUMD

Nu-Med Plus FY 2022: net loss $130K; diluted EPS $0.00

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Nu-Med Plus reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$130KAgainst −$830K in FY 202110-K/A income statement, on EDGAR
  2. Diluted EPS$0.00Against −$0.01 in FY 202110-K/A income statement, on EDGAR
  3. Cash and cash equivalents$73K+527% from $12K in FY 202110-K/A balance sheet, on EDGAR
  4. Cash from operations−$38KAgainst −$207K in FY 202110-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Nu-Med Plus files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. STRATA Skin Sciences SSKN public float $4M, Jun 30, 2025
  2. ENDRA Life Sciences NDRA public float $3M, Jun 30, 2025
  3. Catheter Precision VJET public float $4M, Jun 30, 2025
  4. Global Innovative Platforms GIPL public float $3M, Sep 30, 2025
  5. Interpace Biosciences IDXG public float $3M, Jun 30, 2025